ZS Pharma (ZSPH) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Over-Allotment Option
6/24/2014 10:37:02 AM
COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 891,667 additional shares of common stock. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $112 million.
Help employers find you! Check out all the jobs and post your resume.
comments powered by